Navigation Links
ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference
Date:5/4/2010

availability of corporate partners, (x) the scope of protection ChemoCentryx is able to establish and maintain for intellectual property rights covering its product candidates and technology, (xi) the impact of competitive products and technological changes, (xii) the availability of capital and the cost of capital, (xiii) ChemoCentryx's financial performance, (xiv) developments relating to ChemoCentryx's competitors and other vagaries in the biotechnology industry and (xv) other risks.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and ChemoCentryx undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. Spherix Reports Second Quarter Earnings
10. Tapestry Reports Second Quarter 2007 Results
11. Callisto Reports on Second-Quarter 2007 Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... , March 30, 2015 ... services market is receiving a huge boost from ... population, higher prevalence of non-communicable diseases, and the ... of the primary healthcare services in the country ... by government polyclinics. In response to the substantial ...
(Date:3/30/2015)... 30, 2015 China Nepstar Chain Drugstore ... a leading retail drugstore chain in China based ... announced its unaudited financial results for the fourth ... Financial HighlightsFor the quarter ended December 31, 2014: ... compared to the fourth quarter of 2013 ...
(Date:3/29/2015)... , March 29, 2015  Three-month paliperidone ... to relapse compared to placebo in patients with ... study published this week in the ... . Results of the study ... Drug Application (NDA) filing for three-month paliperidone palmitate ...
Breaking Medicine Technology:Singapore's Vibrant Healthcare Industry an Attractive Market for Advanced Diagnostic Imaging Services, says Frost & Sullivan 2Singapore's Vibrant Healthcare Industry an Attractive Market for Advanced Diagnostic Imaging Services, says Frost & Sullivan 3Singapore's Vibrant Healthcare Industry an Attractive Market for Advanced Diagnostic Imaging Services, says Frost & Sullivan 4China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 11China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 12China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 13China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 14China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 15New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12
... , SAN DIEGO, Dec. 21 ... their highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor, ... The first trial in human subjects, NBI-98854-0801, was a ... in Canada under an approved Clinical Trial Application (CTA) ...
... , CARLSBAD, Calif., Dec. 21 Isis Pharmaceuticals, Inc. ... a $10 million payment from OncoGenex Pharmaceuticals, Inc. (Nasdaq: ... OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). OGX-011 ... that has completed a successful Phase 2 program in patients ...
Cached Medicine Technology:Neurocrine Advances VMAT2 Inhibitor Program 2Neurocrine Advances VMAT2 Inhibitor Program 3Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva 2Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva 3
(Date:3/30/2015)... March 30, 2015 Poo puts a whole ... could be better than Paleo, or better than the latest ... - just released on the app store! , With ... there is a whole other half to that story. Poo ... Poo, users do the dirty work, and then they can ...
(Date:3/30/2015)... Phoenix Arizona (PRWEB) March 30, 2015 ... risk and compliance (GRC) in the global business community, ... (ITAM) ups the ante by managing big data ... capabilities coupled with the already powerful analytic and logic ... , Michael Peters, CEO of Lazarus Alliance said “The ...
(Date:3/30/2015)... Kansas City, Mo. (PRWEB) March 30, 2015 ... BHMEDS App, a mobile library of medications used ... app—available free for iPhone, iPad and Android—is a ... has published annually since 1999. The useful resource ... medications, including purpose, dosage and frequency, side effects, ...
(Date:3/30/2015)... A new recruitment site has been launched to ... career move. , Millions of new jobs are forecast ... skills in the booming data and analytics sectors.* The ... aggregator, pulling in opportunities from both employers and recruitment ... help candidates find suitable big data and analytics jobs ...
(Date:3/30/2015)... CA (PRWEB) March 30, 2015 Cutting-edge ... for Health 2015 Conference because of the opportunities to ... This year’s conference will highlight parents of recovered children, ... parent, Mary Romaniec, will debut her book Victory over ... Whole Family. Free copies of Victory over Autism will ...
Breaking Medicine News(10 mins):Health News:Building on Success: Next Generation of Cyber Crime Prevention Unveiled! 2Health News:Popular Publication on Behavioral Health Medications Now An App 2Health News:New Global Job Site Launched for Big Data and Analytics Job Seekers 2Health News:AutismOne and Focus for Health Highlight Victory over Autism at Major Chicago Conference Following Autism Awareness Month 2Health News:AutismOne and Focus for Health Highlight Victory over Autism at Major Chicago Conference Following Autism Awareness Month 3
... CHAPEL HILL, N.C., April 18 Sales leaders ... services offered by,Best Practices, LLC and in particular ... the Best Practice Database., (http://www.BestPracticeDatabase.com ) Although documents ... many sales leaders have come to find,outstanding value ...
... WASHINGTON, April 18 The following is being,issued ... and Coalition of Full Service Community Hospitals:, ... and the,conflict of interest it creates between a ... fact, over the last year, the House of,Representatives ...
... LeMaitre,Vascular, Inc. (Nasdaq: LMAT ) announced today ... on April 30, 2008, after the close of the,market. ... be hosted,the same day at 5:00 PM ET. The ... participants may listen to the live webcast at, http://www.lemaitre.com/investor, ...
... much as drug treatments , , FRIDAY, April 18 (HealthDay ... in patients with terminal cancer, according to Japanese researchers ... a total of 517 patients with incurable cancer and ... for these patients was supportive expressive group therapy, in ...
... Masimo CEO and CFO to begin after markets ... close at 2:00 p.m. PT (5:00 p.m. ET), ... the inventor of Pulse CO-Oximetry and,Measure-Through-Motion-and-Low-Perfusion pulse oximetry, today announced it,will ... after the market closes on Tuesday, April 29, 2008., A ...
... Benefit Sharp Rehabilitation Services -, SAN DIEGO, ... will hold its second annual charity event, a ... in Point Loma on June 20th and,21st. More ... throughout California are,expected to participate. This year, representatives ...
Cached Medicine News:Health News:Sales Executives Finding Value in Best Practice Database 2Health News:Statement: Congress Should Include the Physician Self-Referral Provision in the Farm Bill for Patients and Communities 2Health News:Talk Therapy Proves Effective for Terminal Cancer Patients 2Health News:Masimo to Report First Quarter 2008 Financial Results on April 29, 2008 2
... is especially designed for the atraumatic removal ... sleek design of this probe minimizes the ... Due to its 24K gold plating, the ... foreign body incarceration. The magnetic probe is ...
... flexible continuous monitoring, the M3 and M4 ... and neonatal patient care. M Series monitors ... includes a basic set of non-invasive parameters ... Optional Multi-Measurement Server extensions offer Mainstream or ...
... the patients side and in transit., ... measurements in a compact package to match ... care, lower acuity environments, and patient transfer., ... patient monitoring, the IntelliVue MP20 Junior has ...
... High-performance monitoring for flexible care settings., ... monitors combine portability and measurement flexibility ... needs of intermediate care environmentsat the ... strong heritage in patient monitoring, IntelliVue ...
Medicine Products: